Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two related deaths, according to the FDA and CDC.

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

Federal drug safety officials have recommended pausing the use of a vaccine ... of chikungunya disease. The FDA said it will conduct an updated benefit-risk assessment for the use of Ixchiq ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

17 serious adverse events, including two deaths, reported among adults 62–89 who received the Ixchiq vaccine. Ixchiq was approved in 2023 and has been distributed globally with 80,000 doses ...

With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...